Realm Therapeutics (RLM) Share Price, News & Analysis

Company Overview

Realm Therapeutics Plc, a biopharmaceutical company, focuses on developing therapies for the treatment of immune-mediated diseases in adults and children. Its product pipeline includes PRO22, a topical gel, which is conducting initial Phase II clinical studies for the treatment of atopic dermatitis. The company was formerly known as PuriCore plc and changed its name to Realm Therapeutics Plc in December 2016. Realm Therapeutics Plc was founded in 2016 and is headquartered in Malvern, Pennsylvania.

Key Stats

• Today's Range: N/A
• 50-Day Range: N/A
• 52-Week Range: N/A
• Volume: 169,853 shs
• Average Volume: 800,861 shs
• Market Capitalization: £13.41 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

RLM Stock Analysis - Frequently Asked Questions

How do I buy shares of Realm Therapeutics?

Shares of RLM stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.

What other stocks do shareholders of Realm Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Realm Therapeutics investors own include Allena Pharmaceuticals (ALNA), Ampliphi Biosciences (APHB), Arbutus Biopharma (ABUS), Aurora Cannabis (ACBFF), AcelRx Pharmaceuticals (ACRX), Aldeyra Therapeutics (ALDX) and Ampio Pharmaceuticals (AMPE).

Industry, Sector and Symbol

• Stock Exchange: LON
• Sector: Medical
• Industry: Biotechnology
• Sub-Industry: Steel Works
• Current Symbol: LON:RLM
• Previous Symbol: LON:PURI
• CIK: N/A
• Web: www.realmtx.com
• Phone: +1-484-3212700
• Fax: N/A
• Employees: N/A
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 10.05
• Quick Ratio: 9.96

Sales & Book Value

• Annual Sales: £501.92 thousand
• Price / Sales: 0.00
• Cash Flow: N/A
• Price / Cash Flow: 0.57
• Book Value: GBX 20.80 per share
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 116,562,000
• Free Float: N/A
• Market Cap: £13.41 million
• Optionable: Not Optionable
• Beta: N/A